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Intestinal epithelial cells (IECs) form a physiochemical barrier that separates the intestinal lumen from the host’s internal milieu
and is critical for electrolyte passage, nutrient absorption, and interaction with commensal microbiota. Moreover, IECs are strongly
involved in the intestinal mucosal inflammatory response as well as in mucosal innate and adaptive immune responses. Cell death
in the intestinal barrier is finely controlled, since alterations may lead to severe disorders, including inflammatory diseases. The
emerging picture indicates that intestinal epithelial cell death is strictly related to the maintenance of tissue homeostasis. This
review is focused on previous reports on different forms of cell death in intestinal epithelium.
1. Introduction
Intestinal homeostasis depends on complex interactions
between microbiota, intestinal epithelium, and host immune
system. Diverse regulatory mechanisms cooperate to main-
tain intestinal homeostasis, and a failure in these pathways
may lead to chronic inflammatory disorders [1–3].
The intestinal epithelium represents a huge surface area
that is lined by a monolayer of intestinal epithelial cells
(IECs), which serve as a barrier to luminal microbes, while
also allowing the absorption of water and nutrients essential
to life, sensing both beneficial and harmful microbes, and
inducing and modulating immune responses [4]. To fulfill
such diverse functions, the intestinal epithelium comprises
several specialized cell types, divided into two main groups:
the absorptive cells, represented by enterocytes, and the secre-
tory cells including Paneth cells, goblet cells, and enteroen-
docrine cells [5–8]. These subsets of IECs are functionally
different and essential to maintain intestinal homeostasis by
separating the intestinal lumen from the underlying lamina
propria and by controlling the crosstalk between microbiota
and subjacent immune cells.
Maintaining barrier function and commensal composi-
tion in healthy intestine is also ensured by a basal activation
of pattern recognition receptors (PRRs), as Toll-like receptor
(TLR) [9], nucleotide oligomerization domain- (NOD-) like
receptor (NLR) [10, 11], and retinoic acid-inducible gene-
(RIG-) I-like receptor (RLR) [12] families, able to detect and
control various microbial structures. PRRs can activate spe-
cific inflammatory transduction signaling that are intimately
interconnected with different cell death pathways [13, 14],
establishing a relationship between host defense mechanisms
and cell death.
Intestinal epithelial homeostasis is maintained by a strict
equilibrium between cell proliferation in the crypt and cell
shedding from the villus tip. In the large and small bowel, dif-
ferentiated enterocytes are removed constantly and replaced
by new cells originated by undifferentiated adult intestinal
stem cells, located in the third or fourth position counted
from the base of the crypt [15]. These new cells migrate from
the base of the crypt to the apical zone of the intestine under-
goingmaturation.The epithelial layer displays a strict balance
between cell proliferation and cell death in order to maintain
the intestinal barrier [16].
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Figure 1: Cell death pathways. Apoptosis, necroptosis, and pyroptosis are programmed forms of cell death, while necrosis represents an
unregulated cell death. Autophagy is a survival pathway that if it is excessive or uncontrolled, it promotes cell death. Fas-associated protein
with a death domain (FADD); receptor-interacting interacting protein 1 (RIP1); receptor-interacting interacting protein (RIP3); mixed lineage
kinase domain-like (MLKL); danger-associated molecular patterns (DAMPs); pathogen-associated molecular patterns (PAMPs); nod-like
receptor family, pyrin domain containing (NLRP)3; apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC);
autophagy-related genes (ATG); autophagy related 16-like 1 (ATG16L1); light chain 3 (LC3II); ER: endoplasmic reticulum.
In this review we will describe the relationship between
themain forms of epithelial cell death, apoptosis, necrosis and
necroptosis, and the intestinal epithelium during gut home-
ostasis and inflammation. Moreover, two secondary forms of
cell death will be shown (Figure 1).
2. Cell Death and Intestinal Epithelium
Cell death is a crucial process for tissue development and
equilibrium to eliminate superfluous, damaged, or aged cells
and represents a key for the homeostasis reestablishment
after an acute or chronic insult, limiting the propagation of
the inflammatory stimuli to prevent tissue loss of function
[17]. This is of particular importance for the gastrointestinal
tract, since the intestinal epithelium undergoes continuous
and rapid self-renewal, while it is permanently exposed to
a plethora of antigens and potential pathogens which are
present in the food and in the microbial flora. As a conse-
quence, epithelial cell renewal and cell death need to be
tightly regulated because inappropriate cell death responses
inexorably lead to the development of diseases, like inflam-
matory disorders and cancer [18, 19]. Historically, cell death
has been divided in unregulated forms, such as necrosis, and
programmed forms, such as apoptosis and necroptosis.
Traditionally, necrosis has been described as a passive
and uncontrolled process, initiated by external factors such
as ischemia-reperfusion, toxins, viral, and bacterial infections
and is characterized by a rapid breakdown of the cell mem-
brane, resulting in the release of intracellular compounds into
the extracellular space with activation of the immune system
[20, 21].
Apoptosis is a process relying on caspase activation that
when it is excessive, it may may impair the epithelial barrier,
leading to severe gut pathology [16, 22, 23]. Apoptosis has
long been considered the only form of regulated cell death,
while the existence of additional forms of controlled cell
death is now well established [24, 25]. The latter can be
triggered independently of apoptosis induction or as back-up
safety mechanisms when the apoptotic machinery does not
operate properly, as a result of genetic mutations or chemical
or microbial inhibition.
Necroptosis is a recently identified form of programmed
cell death that is, differently from apoptosis, negatively regu-
lated by caspases and depending on the kinase activity of
receptor-interacting proteins (RIP) [26, 27]. Necroptosis
shows morphological features similar to necrosis, but, as
apoptosis, is strictly regulated by a multiprotein platform. It
is characterized by a rapid membrane breakdown, resulting
in the release of intracellular compounds, that is, Damage-
Associated Molecular Patterns (DAMPs), such as high-
mobility group box 1 (HMGB1) protein, heat shock proteins,
DNA, and RNA, that activate PRRs to further promote an
inflammatory response [25, 28].
Given the complex structure of the intestinal epithelium,
proliferation, differentiation, and cell death must be tightly
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controlled. Excessive cell death might result in a breakdown
of the intestinal barrier with subsequent uncontrolled access
of bacteria into the gut wall and inflammation [1]. On the
contrary, resistance to cell death is believed to be a driving
force of tumor development in the gut [28].
3. Apoptosis
Apoptosis can be initiated by a wide variety of stimuli includ-
ingDNAdamage, nutrient deficiency, endoplasmic reticulum
(ER) stress, growth factor withdrawal, heat shock, develop-
mental cues, and ligation of death-receptors on the cell sur-
face [22, 23] through the activation of apoptotic caspases
[23, 29].
Two sites of epithelial cell death have been described
along the length of the villus: the first takes place in the crypt
at the level of the stem and early transit cells and is sometimes
referred to as “spontaneous” apoptosis and the second at the
villus tip or to the surface epithelial cuff in the colon, where
epithelial cells, after travelling from the crypt base, differenti-
ate and then die from anoikis [30].The latter is a special form
of programmed cell death induced in anchorage-dependent
cells after detachment from their matrix [31, 32]. Mechanisms
control this process are still unsettled [30]. Indeed, cell
detachment is suggested to coincidewithmorphological hall-
marks of apoptotic cell death, but a clear causal relationship
between cell detachment and apoptosis has not yet been
proven [31–33].
A number of studies implicate that cell shedding is
actively regulated and involves the proapoptotic molecule
caspase-3 [34, 35] and that the block of caspases inhibits the
tumor necrosis factor- (TNF-) induced cell shedding [35].
Furthermore, it has been reported that TNF or lipopolysac-
charide (LPS) stimulation increases apoptosis and conse-
quent cell shedding and is associated with barrier loss [36].
Differently, several studies on mouse models did not support
the apoptotic hallmark of shedding epithelial cells. Studies on
mice null for proapoptotic molecules, caspase-3, caspase-8,
and Fas-associated protein with a death domain (FADD) did
not show any morphological alterations in the development
of the gastrointestinal epithelium, suggesting that apoptosis
is not required for intestinal turnover [37, 38]. Furthermore,
experimental data obtained with the use of Necrostatin-
1, a chemical inhibitor of the kinase receptor interacting
protein (RIP)1, showed that murine enterocyte shedding in
the small intestine is mostly associated with a nonapoptotic
programmed cell death, mediated by RIP1 [39]. Recent stud-
ies with RIP1 knock-outmice showed that the loss of caspase-
8 or TNFR1 completely prevented the intestinal pathology,
suggesting a RIP1 essential role in protecting the intestinal
epithelia from apoptosis [40–42].
The most convincing hypothesis is that epithelial cell
shedding might be a passive process induced by high density
of cells in constrained spaces at the villus tip and, thus, the
shedding-associated cell deathmight be a consequence rather
than a cause of shedding [43].
Alongside with intestinal cell shedding, patterns of spon-
taneous apoptosis, p53 mediated, have been described within
the crypt region, but with a different regulation between
the large and small intestine [44, 45]. Indeed, it concerns stem
cell region in the small intestine but it is rarely found in the
colonic crypts. Accordingly, the antiapoptotic gene Bcl-2 (B-
cell CLL/lymphoma 2) [45] is barely expressed in the small
intestine and strongly expressed at the base of the colonic
crypts. Interestingly, differences in Bcl-2 expression and cell
death regulation can account for the variability in tumor
prevalence between the small and large intestines [46]. Two
other studies on mouse models showed that Bcl-2 and Bax-
null mice displayed similar levels of spontaneous apoptosis in
small intestinal crypts compared to their wild-type strains
[47, 48].
Altogether these findings highlight that the role of apop-
tosis in physiology of healthy gut is still controversial.
4. Apoptosis and Intestinal Inflammation
An increasing body of evidence suggests that apoptotic
signaling may promote inflammatory processes by releasing
extracellular vesicles and various chemokines, which may
potentially recruit and activate immune cells [49].
Although the role of apoptosis in the structural integrity
of the gut is still controversial, there is little doubt that dysreg-
ulated or excessive apoptosis can lead to severe gut disorders.
Accordingly, several studies reported that mice with elevated
apoptosis in the intestinal epitheliummore likely develop gut
inflammation [46, 50, 51].
Mice lacking nuclear factor kappa B essential modula-
tor (NEMO) in intestinal epithelial cells (IECs) developed
spontaneous colitis shortly after the birth due to excessive
TNF-dependent apoptosis, followed by epithelial barrier
breakdown and translocation of bacteria into the bowel wall.
The inhibition of TNF signaling avoided the development of
colitis [52]. Moreover, silencing of other members of the NF-
𝜅B pathway, REL-A, transforming growth factor-activated
kinase (TAK)1 or both I𝜅B kinase (IKK)1 and IKK2, in IECs
increased murine susceptibility to spontaneous colitis, pro-
viding a strong link among NF-𝜅B activity, epithelial apopto-
sis, and intestinal inflammation [53–55].
Furthermore, mice with IEC-specific deletion of the tran-
scription factor Stat3 showed an increased sensitivity to apop-
tosis upon treatment with dextran sodium sulfate (DSS) [56].
Similarly, XBP1 knock-out mice developed a spontaneous
enteritis associated to Paneth cell dysfunction and increased
apoptosis of intestinal barrier cells [57].
A dysregulated apoptosis has also been suggested to play
a role in the pathogenesis of human inflammatory bowel
disease (IBD), including Crohn’s disease (CD) and ulcerative
colitis (UC). It was reported that an excessive cell shedding
and barrier loss in IBD patients in remission predict a disease
relapse [58]. Moreover, various apoptotic bodies were found
in colonic biopsies routinely taken from patients with active
UC, especially in those who required surgery compared with
those only treated with medication, suggesting a correlation
between IEC apoptosis and disease severity [59]. A twofold
increased apoptosis was observed in colonic samples of
CD patients compared to controls. Interestingly, levels of
apoptosis returned to control levels when patients underwent
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anti-TNF therapy, suggesting a role of TNF in epithelial cell
death [60, 61].
T cells in the intestinalmucosa of IBDpatientswere found
to be resistant to multiple apoptotic signals, showing defects
in the control of programmed cell death, thus suggesting a
possible mechanism to explain why inflammation is resilient
to resolution in IBD patients [62–64].
Cell death in the intestinal epithelium seems also to
be regulated by bacterial communities. Increased apoptosis
has been demonstrated in patients infected with human
pathogens, including Salmonella, Shigella, enteropathogenic
Escherichia coli, human immunodeficiency virus type 1,
Helicobacter pylori, and Cryptosporidium parvum [65–67].
In conclusion, although these studies show a relationship
between IBD pathogenesis and altered apoptosis, it is still
unclear if the latter is a primary event or a secondary to
inflammation.
5. Necrosis
Necrosis is considered as an accidental and uncontrolled
cell death, frequently associated to disorders such as ische-
mia-reperfusion (IR) injury, neurodegeneration, intestinal
ischemia, and infarction [20, 21, 68, 69]. During necrosis, cell
and organelles swell and break down with subsequent release
of cellular content into the microenvironment, causing the
inflammatory response. Common players in necrotic cell
death are calcium, which causes mitochondrial calcium over-
load, bioenergetics effects as well as activation of proteases
and phospholipases, and reactive oxygen species (ROS),
which produce mitochondrial dysfunction, ion balance
deregulation, and loss of membrane integrity [69–71]. Mem-
brane destabilization is also mediated by additional factors,
such as acid-sphingomyelinase (ASM), phospholipase A(2)
(PLA(2)), and calpains [72]. It has been shown that necrotic
cells release immunomodulatory factors causing the activa-
tion of the immune response [21, 70, 71].
Necrotic cells have been observed in the colonic epithe-
lium of CD patients, within inflamed as well as uninflamed
areas, suggesting that increased necrosis might be a primary,
rather than a secondary, mechanism for the development
of the disease [73]. Furthermore, the histological analysis
revealed, in subjects with IBD, the presence of necrotic
intestinal epithelial cells, within the crypts, even during the
inactive phase of the disease, implying that necrosis occurs
more frequently than expected [74]. In a recent study, the
necrosis of Paneth cells in the terminal ileum has been linked
to the pathogenesis of IBD [37]. Necrosis as well dysfunction
of Paneth cells could explain the decreased production of
antimicrobial peptides in IBD [75].
However, whether IEC necrosis normally occurs in the
mucosa of the gastrointestinal tract or is strictly associated to
inflammation remains still elusive.
Necrosis is also believed to play a fundamental role
in infectious gastrointestinal diseases caused by pathogens,
since it has been showed that it can be driven by several
cytotoxic bacteria [76, 77].
6. Necroptosis
Recently, a new caspase-independent mode of programmed
cell death, termed necroptosis, has been identified [31, 78, 79],
also in the intestinal epithelium [23, 37, 38].
Although necroptosis shows morphological features sim-
ilar to necrosis, it is highly regulated by an intracellular
protein platform, largely overlapping with that of apoptosis
[25, 26, 79–81]. However, while apoptosis depends on caspase
activation, necroptosis is negatively regulated by caspases and
needs the intervention of the kinase RIP3 that is thought to
be a necroptosis key mediator [82–85]. It is conceivable that
when the apoptotic caspases fail to be activated, then cells
undergo necroptosis as an alternative death pathway [79, 84].
Different endogenous or exogenous stimuli, such as the
TNF, ligation of Fas, or the engagement of innate immunity
sensors [79, 83], may trigger the necroptosis by activating
RIP3 [82–85].
Currently, the most informative studies of necroptosis
pathway derive from systems that use TNF as a trigger [37, 85,
86], inducing three interrelated signaling pathways, initiated
by distinct scaffolding complexes named complex I, complex
II, and complex IIb, leading the cell to three different out-
comes [23–25]. Upon binding to its receptor, the TNF
receptor 1 (TNFR1), the TNF forms the membrane-bound
complex I, consisting of the TNF receptor-associated pro-
teins with a death domain (TRADD), the TNFR-associated
factor 2 (TRAF2), and RIP1 [86, 87]. After deubiquitination
that destabilizes complex I, RIP1 recruits the Fas-associated
protein with a death domain (FADD) and caspase-8 to form
complex II, the classical extrinsic apoptotic pathway [87]. If
present, RIP3 forms the complex IIb, also known as necro-
some [88].The inhibition of the caspase-8 and the simultane-
ous increase of RIP3 promote the activity of the necrosome
resulting in necroptosis [42, 84, 89] (Figure 2).
At present, little is known about the events occurring
downstream RIP1 and RIP3 that regulate necroptosis. It is
suggested that the RIP homotypic interaction motif (RHIM)
on RIP3 and RIP1 allows their interaction and is required for
necroptosis induction. Afterwards, RIP1 and RIP3 assemble
into cytosolic filamentous structures beta-amyloids, although
it is unclear whether they represent a real signaling platform
or a postevent accumulation of the two interacting kinases
[21, 25, 90]. The RIP1-RIP3 complex drives the RIP3 auto-
phosphorylation which, in turn, phosphorylates the mixed
lineage kinase domain-like (MLKL), leading to membrane
permeabilization [88, 91–96]. The occurrence of a cross-
regulation between apoptotic and necroptotic pathways to
maintain cell homeostasis has been suggested; accordingly,
necroptosis may act as an emergency back-up death pathway
when the apoptotic cascade is impaired [79]. Several in
vivo studies demonstrated a role of FADD and caspase-8 to
regulate necroptosis during embryonic development, since
excessive necroptosis caused the death of the embryos [97,
98].
Recent papers on knock-out mice showed kinase-
independent RIP1 functions regulating homeostasis and
preventing inflammation in barrier tissues by inhibiting
epithelial cell apoptosis and necroptosis [40, 41]. Indeed,
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IEC-specific RIP1 deletion caused apoptosis, villus atrophy,
loss of goblet and Paneth cells, and premature death in
mice. Epithelial FADD ablation inhibited IEC apoptosis and
prevented the premature death ofmicewith IEC-specificRIP1
knockout.However,mice lacking bothRIP1 and the apoptotic
factor FADD in IECs displayed RIP3-dependent necroptosis,
Paneth cell loss, and focal erosive inflammatory lesions in the
colon [41].
7. Necroptosis and Intestinal Inflammation
Necroptosis, similarly to necrosis, is characterized by the
release into the extracellular milieu of immunogenic cytosol
content, including alarmins andDamage-AssociatedMolecu-
lar Patterns (DAMPS), that lead to the activation of PRRs, for
example, TLRs triggering inflammation [99–102]. Necropto-
sis has been suggested to play a role in the pathogenesis of
several inflammatory disorders, including IBD [23, 27, 28, 37,
89].
Caspase-8 and FADDnull mice in IECs exhibited chronic
inflammation characterized by extensive epithelial necropto-
sis with amarked reduction in Paneth cell number and conse-
quent decrease of antimicrobial peptide production [36–38].
However, it is still uncertain whether necroptosis promotes
inflammation or if the latter depends on the specific depletion
of Paneth cells [37, 75]. High levels of RIP3 have also been
shown in both adult [37] and pediatric [103] CD patients.
However, necroptotic triggering factors remain unclear in
both mice and humans [101].
8. Novelties in Cell Death:
Pyroptosis and Autophagy
Pyroptosis, initially described in immune cells during antimi-
crobial response [104], is a caspase-1 or caspase-11-dependent
regulated type of cell death that plays a central role in
inflammation and immunity [105–107].
Caspase-1-dependent pyroptosis [107, 108], has been bet-
ter described than caspase-11-dependent pyroptosis [109].
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Pyroptosis is commenced by the interaction between patho-
gen-associated molecular patterns (PAMPs) and intracellular
PRRs leading to the formation of a multiprotein complex
called inflammasome [110] which is composed of dimers of
the adaptor protein apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC). A role of
RIP3 in activation of inflammasome has also been reported
[111]. Four subfamilies of inflammasome have been defined:
nucleotide-binding domain, leucine-rich-repeat-containing
family, pyrin domain-containing (NLRP)1, NLRP3, NLR
family CARD domain-containing protein 4 (NLRC4), and
absent in melanoma 2 (AIM2). Currently, the best character-
ized inflammasome is NLRP3 [112]. Stimulation with specific
microbial and endogenousmolecules triggers inflammasome
assembly and caspase-1 activation that leads to the secretion
of proinflammatory cytokines, including interleukin-1𝛽 (IL-
1𝛽) or interleukin-18 (IL-18) [110]. In the gut, the inflam-
masome activation has been largely associated with NOD-
like receptors and DAMPs that start the enzymatic cascade
triggering the inflammatory process [113–115]. The caspase-1
inflammasome is crucial in maintaining intestinal homeosta-
sis. Indeed, mice deficient in NLRP3, NLRP6, NLRC4, ASC,
caspase-1, and IL-18 are susceptible to DSS-induced colitis
[116]. Interestingly, mice deficient in caspase-11 are also sus-
ceptible to DSS-induced colitis, but independently of IL-1𝛽
and IL-18 secretion, suggesting the existence of a mechanism
distinct from classical inflammasome function in the gut [117,
118]. Indeed, a protectivemechanismof caspase-11-dependent
pyroptosis in the intestine has been postulated, whose
deficiency might drive the disease [119].
Autophagy represents a homeostatic cellular mechanism
for the turnover of organelles and proteins, through a lyso-
some-dependent degradation pathway [120]. During star-
vation or other stress conditions, autophagy facilitates cell
survival through the recycling of metabolic precursors, while
excessive or uncontrolled autophagy promotes cell death and
morbidity [121].The concept of autophagic cell death is based
on observations of increased morphological features (e.g.,
accumulation of autophagic vesicles) in dying cells [122].
Targeted cytoplasmic constituents are included in a double-
membraned vesicle known as autophagosome, which is then
fused with a lysosome and its cargo degraded and recycled
[123]. Some authors suggested that autophagy might play a
role in regulating the outcome of other programmed cell
death forms as apoptosis, necroptosis, and pyroptosis [114,
121, 124].
Autophagy-related genes (ATG) are essential regulators
of autophagy in development and most other stages of adult
life in mice [125]. Homozygous genetic knockouts of most
ATG genes (e.g., ATG3, ATG 5, ATG 6, ATG 7, ATG 9, and
ATG16L1) in mice are developmentally lethal [125].
Autophagy contributes to the maintenance of intesti-
nal homeostasis, being implicated in nutrient sensing and
turnover, as in the control of glucose and amino-acids level
and in the recycling of lipids and somemicronutrients as iron
[126]. A role of autophagy in the modulation of intestinal
microbiota and response to bacterial infection has also
been recognized [127]. Actually, in intestinal cells, autophagy
operates as part of the cell-intrinsic innate immunity program
to restrict bacterial replication and dissemination [127].
The identification of the single nucleotide polymorphism
(SNP) of the autophagy-related 16-like 1 (ATG16L1) gene,
increasing the susceptibility to CD, established a link between
autophagy and IBD [128, 129]. Recently, a defective autophagy
has been also related to the activation of inflammasome,
induction of pyroptosis, and increased susceptibility to colitis
in mouse models [13, 130].
9. Conclusions
Preserving the integrity of the epithelial barrier by regulating
the rate of cell death is considered crucial for maintaining the
intestinal homeostasis. Failure of barrier functions, due to an
unregulated or excessive cell death, leads to the entry of nox-
ious agents and aberrant stimulation of the intestinal immune
system. It is worth noting that the same immune pathways
that mediate pathogen recognition and inflammation may
themselves trigger cell death, emphasizing the role of the
latter in host defense. Besides, the identification of the cross-
regulatory relationship between different forms of cell death
and their intersection with the inflammatory response are
fundamental issues to understand their involvement in the
development of human intestinal diseases.
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